Literature DB >> 6356272

The immunobiology of leishmaniasis.

R D Pearson, D A Wheeler, L H Harrison, H D Kay.   

Abstract

Members of the genus Leishmania are important intracellular pathogens that produce either cutaneous, mucocutaneous, or visceral disease in many areas of the world. In humans as well as in other mammals, the parasite is inoculated through the skin as a flagellated, extracellular promastigote by its arthropod vector, the sandfly. Once in its mammalian host, the promastigote converts to its amastigote stage, which lacks an exteriorized flagellum and is found solely within mononuclear phagocytes during established infection. In vitro, human monocyte-derived macrophages and peritoneal macrophages from several species of rodents can ingest both promastigotes and amastigotes, and they can permit intracellular multiplication of amastigotes only. Although serum factors may play a role in the pathogenesis of the disease and in protection against reinfection, the resolution of leishmaniasis is dependent primarily on cell-mediated immune responses. There appears to be a complicated interplay between cell-mediated helper and suppressor activities. The outcome of infection in each type of leishmaniasis depends on the complex and intriguing interaction of virulence factors inherent in the parasite and genetically determined host defense mechanisms.

Entities:  

Mesh:

Year:  1983        PMID: 6356272     DOI: 10.1093/clinids/5.5.907

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  39 in total

1.  Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis.

Authors:  S Mukhopadhyay; S Bhattacharyya; R Majhi; T De; K Naskar; S Majumdar; S Roy
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  New Zealand black mice are immunologically resistant to high-dose, but not low-dose Leishmania mexicana infection.

Authors:  R C Dorea; J Alexander; G Gallagher
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route.

Authors:  C A Power; G Wei; P A Bretscher
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

4.  Human visceral leishmaniasis: decrease in serum cholesterol as a function of splenic parasite load.

Authors:  J Ghosh; C S Lal; K Pandey; V N R Das; P Das; K Roychoudhury; S Roy
Journal:  Ann Trop Med Parasitol       Date:  2011-04

Review 5.  Biochemistry of the Leishmania species.

Authors:  R H Glew; A K Saha; S Das; A T Remaley
Journal:  Microbiol Rev       Date:  1988-12

6.  The effects of macrophage source on the mechanism of phagocytosis and intracellular survival of Leishmania.

Authors:  Chia-Hung Christine Hsiao; Norikiyo Ueno; Jian Q Shao; Kristin R Schroeder; Kenneth C Moore; John E Donelson; Mary E Wilson
Journal:  Microbes Infect       Date:  2011-06-30       Impact factor: 2.700

7.  Studies on the arginase, 5'-nucleotidase and lysozyme activity by monocytes from visceral leishmaniasis patients.

Authors:  Pramod Kumar; Ramesh Kumar; Haushila Pandey; Shyam Sundar; Kalpana Pai
Journal:  J Parasit Dis       Date:  2011-09-06

8.  Cyclosporin A enhances elimination of intracellular L. major parasites by murine macrophages.

Authors:  C Bogdan; H Streck; M Röllinghoff; W Solbach
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

9.  Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.

Authors:  Tejinder Kaur; Ankita Thakur; Sukhbir Kaur
Journal:  J Parasit Dis       Date:  2012-09-06

10.  Interferon-gamma in starch microparticles: nitric oxide-generating activity in vitro and antileishmanial effect in mice.

Authors:  L Degling; P Stjärnkvist; I Sjöholm
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.